FRIDAY, July 20 (HealthDay News) -- Kyprolis (carfilzomib) has been approved by the U.S. Food and Drug Administration to treat certain people with multiple myeloma who have already been given at least two prior therapies.
More than 21,000 people in the United States are expected to be diagnosed with multiple myeloma this year, and about 10,700 will die from it, the American Cancer Society estimates.
Kyprolis has been approved for people treated previously with bortezomib and an immunomodulatory therapy such as thalidomide.
The most common side effects observed during clinical testing of Kyprolis included fatigue, low blood cell counts, low platelet counts, diarrhea, and fever. More serious but less common adverse reactions included heart failure and shortness of breath, the FDA said.
Kyprolis is marketed by San Francisco-based Onyx Pharmaceuticals.
Medline Plus has more about multiple myeloma.